Pfizer Inc. (PFE)

Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera

Novo Nordisk (NYSE:NVO) has outbid Pfizer Inc (NYSE:PFE, ETR:PFE) in a heated contest for obesity-focused biotech Metsera (NASDAQ:MTSR), with the Danish drugmaker's revised offer valuing the company at roughly $10 billion, compared with Pfizer's $8.1 billion proposal. Metsera's board on Tuesday declared Novo Nordisk's amended bid “superior,” setting the stage for a potential acquisition that could reshape the obesity treatment landscape.

Pfizer and Novo Nordisk both raise bids for Metsera

CNBC's David Faber breaks down the latest details about a bidding war between Pfizer and Novo Nordisk for Metsera.

Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools

Pfizer posts Q3 earnings beat and raises EPS guidance, but weaker COVID product sales weigh on overall revenue momentum.

Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo

A Delaware judge said on Tuesday she did not see in a preliminary evaluation the need to involve the court in the bidding war for Metsera between Pfizer and Novo Nordisk, but did schedule another hearing for 3:15 pm ET on Wednesday to review the process.

Pfizer reports strong Q3 earnings, raises full-year profit guidance

Pfizer Inc (NYSE:PFE, ETR:PFE) reported third quarter financial results that topped Wall Street expectations despite a year-over-year drop in earnings and sales, while raising its full-year profit guidance. The company reported Q3 revenue of $16.7 billion, slightly above analyst estimates of $16.55 billion, representing a 7% decline compared with the same period last year.

Here's What Key Metrics Tell Us About Pfizer (PFE) Q3 Earnings

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid

The new offer constitutes a superior company proposal to Pfizer's bid, Metsera said.

Pfizer's Q3 Earnings Beat on Top and Bottom Lines

Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 consensus and revenue of $16.65 billion versus $16.50 billion expected.

Pfizer's revenue falls as COVID sales and vaccine recommendations continue to fade

The full-year outlook was lifted, but the stock lost ground.

Pfizer's Q3: Stagnation Continues

Pfizer reported another quarter of stagnation, with Q3 2025 revenue and EPS both declining year-over-year despite beating consensus estimates. PFE's revenue mix remains weak, with Primary Care sales dropping 15.6% and only Oncology showing growth ahead of inflation; management guidance remains largely unchanged. The forward P/E ratio is expected to stagnate, and low valuation multiples reflect poor growth prospects, making sector comparisons misleading.

Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up

Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday.

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit escalates a heated standoff between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the blockbuster weight loss drug market.

Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera

Lawsuit says the proposed merger of the weight-loss drugmakers could kill off a smaller competitor.

Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.

Novo Nordisk changes tack with bold raid on Pfizer obesity deal

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market under a new CEO and board.

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

Metsera has become the obesity drug market's hottest ticket.

10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)

The article analyzes the top large-cap value (GASV) stocks using YCharts' Value Score and Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Ten of eighteen 'safer' lowest-priced GASV stocks, including ET, MPLX, YRD, VZ, BMY, TFC, T, SU, MFC, and BBVA, are considered buyable in October. Analyst projections suggest the top ten GASV stocks could deliver average net gains of 38.01% by October 2026, with Lexinfintech Holdings leading potential returns.

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).

What Analyst Projections for Key Metrics Reveal About Pfizer (PFE) Q3 Earnings

Evaluate the expected performance of Pfizer (PFE) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade

There's no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment.

3 Stocks Under $30: Where to Put $1,000 to Work Today

Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Pfizer's Headwinds May Already Be In The Price

Pfizer faces significant revenue headwinds from patent expiries, COVID product declines, and generic competition, but these risks are largely priced in. PFE's valuation is historically low at ~8x earnings, reflecting aggressive patent cliff assumptions and conservative growth projections for existing products. Pipeline and acquisition success, especially in obesity/diabetes, could drive capital appreciation, with even partial wins supporting a rerating toward historical multiples.

PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

2 Safer High-Yield Stocks That Can Pay Boomers for Life

Baby Boomers should be looking to play things a bit more cautiously as stock valuations begin to climb across the board.

My Top 3 Pharma Stocks

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.

Pfizer's Q3 Non-Oncology Performance: Here's What to Expect

Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare valuations from Eli Lilly And Co (NYSE:LLY) to Pfizer Inc (NYSE:PFE).

What's Behind The Slump In Pfizer Stock?

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around $138 billion.